Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749343 | 0.84 | PRCP (0.56) | PRCPGRM5HRH1CYP2D6KDM4E | |
| SCHEMBL14749321 | 0.84 | PRCP (0.55) | PRCPGRM5HRH1CYP2D6NAMPT | |
| SCHEMBL14749320 | 0.82 | PRCP (0.58) | PRCPGRM5HRH1CYP2D6NAMPT | |
| SCHEMBL14749342 | 0.82 | PRCP (0.53) | PRCPGRM5HRH1CYP2D6KDM4E | |
| SCHEMBL12183983 | 0.82 | PRCP (0.64) | PRCPNAMPTKDM4E | |
| SCHEMBL14749328 | 0.81 | PRCP (0.61) | PRCPGRM5NAMPT | |
| SCHEMBL14749350 | 0.81 | PRCP (0.53) | PRCPGRM5GFER | |
| SCHEMBL14736875 | 0.81 | PRCP (0.59) | PRCPGRM5NAMPTKDM4E | |
| SCHEMBL14749330 | 0.81 | PRCP (0.57) | PRCPGRM5NAMPTGFER | |
| SCHEMBL14749364 | 0.81 | PRCP (0.55) | PRCPHRH1NAMPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885GRM5 3785/4885HRH1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.